Home / Science / Twist Bioscience Launches Rapid MRD Test
Twist Bioscience Launches Rapid MRD Test
29 Oct
Summary
- Twist Bioscience launched a new rapid test for cancer research.
- The test supports tumor-informed molecular residual disease investigations.
- It offers personalized panels with quick turnaround times starting within one day.
Twist Bioscience Corporation announced the launch of Twist MRD Express on October 29, 2026. This new offering provides custom panels manufactured at scale with a rapid turnaround time, beginning within one day.
These panels are designed to assist cancer researchers in investigating tumor-associated genomic variants. They support crucial studies in oncology research, biomarker discovery, and assay development.
The technology addresses molecular residual disease (MRD), which involves the presence of residual tumor-derived molecules after treatment. Twist MRD Express facilitates personalized, tumor-informed MRD testing, enhancing sensitivity without compromising speed.
Twist's platform aims to scale with the ambitions of MRD providers. The high-throughput DNA synthesis platform can support growing demand as customers expand testing volumes and develop more comprehensive panels.
